

LIVE!

## LIVE WEB BROADCAST on [iMedicus.ca](http://iMedicus.ca)

WEDNESDAY, OCTOBER 30<sup>TH</sup>, 2019  
6:30 P.M. ET

# The Evolving Landscape of Cutaneous Squamous Cell Carcinoma Treatment: Updates on Immunotherapy Treatment



### MARCUS BUTLER, MD

Assistant Professor, Department of Medicine  
University of Toronto  
Director  
Princess Margaret Immune Monitoring Laboratory  
Toronto, ON

TUNE  
IN!

### PROGRAM DESCRIPTION:

Cutaneous Squamous Cell Carcinoma (cSCC) is the second most common form of skin cancer in Canada, with an estimated 16,000+ patients nationally. It is forecasted that anywhere from 200-700 of these patients have locally advanced or metastatic cSCC.

This livestreaming program targets surgeons from a number of specialties that are involved in the treatment of cSCC patients, to advise on a new, recently approved curative treatment. Cemiplimab is a fully-human monoclonal antibody that is the first and only biologic immunotherapy treatment specifically approved and available for adult patients with metastatic or locally advanced cSCC.

**JOIN US ON OCTOBER 30<sup>TH</sup> TO LEARN MORE!**

**INTERACT LIVE!**

Text, email or chat with the panelist and have your questions answered LIVE.



For more information: [info@iMedicus.ca](mailto:info@iMedicus.ca)



The Melanoma Network of Canada (MNC) is a national, patient-led, charitable organization. The mission of MNC is to support individuals whose lives have been changed by melanoma. We are advancing the prevention of melanoma and skin cancer through advocacy and education.

[www.melanomanetwork.ca](http://www.melanomanetwork.ca)

PRESENTED BY:  
[eocipharma.com](http://eocipharma.com)

